Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CHMP OK Puts Merck KGaA's Cladribine Pill On EU Home Stretch After Long Trek

Executive Summary

Merck of Germany's oral multiple sclerosis medicine cladribine looks set to finally get EU approval. But the long, slow race it has had to endure - and time lost getting there - may curb sales.

You may also be interested in...



2Q Pharma Results Preview: Pfizer, Allergan, Teva, Merck KGaA & Shire

Pfizer will anchor the final week of major biopharma earnings calls, facing the same question as every firm with massive stockpiles of cash: When are you going to spend that money on a transformative M&A deal?

German Merck Aims To Lift Its UK R&D Efforts, Despite Brexit Uncertainty

Germany's Merck Group plans to bolster its biopharma R&D activities in Britain - despite Brexit - on grounds the UK is too key and dynamic a player in the life sciences sphere not to - and because the conglomerate needs to be there to help ensure its evolution into a top oncology and immuno-oncology innovator.

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

Topics

Related Companies

UsernamePublicRestriction

Register

SC099006

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel